StreetInsider.com News Articles

Form SCHEDULE 13G/A Pyxis Oncology, Inc. Filed by: Laurion Capital Management LP

Mon, 09 Feb 2026 11:23:00 -0500

si-local-file:///var/storage/secattach/20260209/25966607.html

Form SCHEDULE 13G/A Pyxis Oncology, Inc. Filed by: Laurion Capital Management LP

Mon, 09 Feb 2026 11:23:00 -0500

si-local-file:///var/storage/secattach/20260209/25966607.html

Pyxis Oncology appoints Tom Civik as interim CEO

Fri, 06 Feb 2026 16:11:57 -0500

Pyxis Oncology Inc. (NASDAQ: PYXS) announced a leadership change effective February 2, 2026. Dr. Lara Sullivan ceased serving as Chief Executive Officer and principal executive officer of the company.

The board of directors appointed Tom Civik, a current director, as interim Chief Executive Officer and principal executive officer. Civik previously served as President and Chief Executive Officer of Five Prime Therapeutics from April 2020 to April 2021. He most recently served as Chairperson of the Board of ImCheck Therapeutics and Repare Therapeutics.

The company entered into an interim chief executive officer employment agreement with Civik. His service as interim CEO will continue

Pyxis Oncology appoints Tom Civik as interim CEO

Fri, 06 Feb 2026 16:11:57 -0500

The company entered into an interim chief executive officer employment agreement with Civik. His service as interim CEO will continue

Form 8-K Pyxis Oncology, Inc. For: Feb 06

Fri, 06 Feb 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260206/25961540.html

Form 8-K Pyxis Oncology, Inc. For: Feb 06

Fri, 06 Feb 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260206/25961540.html

Form 4 Pyxis Oncology, Inc. For: Feb 03 Filed by: Civik Thomas

Thu, 05 Feb 2026 20:38:00 -0500

si-local-file:///var/storage/secattach/20260205/25956720.html

Form 4 Pyxis Oncology, Inc. For: Feb 03 Filed by: Civik Thomas

Thu, 05 Feb 2026 20:38:00 -0500

si-local-file:///var/storage/secattach/20260205/25956720.html

Pyxis Oncology names Thomas Civik interim CEO as Sullivan steps down

Tue, 03 Feb 2026 06:45:29 -0500

Pyxis Oncology Inc. (NASDAQ: PYXS) announced Thomas Civik has been appointed interim chief executive officer, effective immediately, replacing Lara S. Sullivan, M.D., who stepped down from her roles as president, CEO and chief medical officer.

Civik, a member of Pyxis Oncology's board of directors since the company's initial public offering, brings extensive biotechnology experience to the role. He previously served as president and CEO of Five Prime Therapeutics, leading the company through its $1.9 billion acquisition by Amgen in April 2021. Before that, he held the position of chief commercial officer at Foundation Medicine and spent 17 years at Genentech in

Pyxis Oncology names Thomas Civik interim CEO as Sullivan steps down

Tue, 03 Feb 2026 06:45:29 -0500

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

Tue, 03 Feb 2026 06:45:00 -0500

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company’s strategic and clinical goals.

Thomas Civik, a member of Pyxis Oncology’s Board of Directors since the Company’s IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer.

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

Tue, 03 Feb 2026 06:45:00 -0500

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Mon, 12 Jan 2026 10:14:00 -0500

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026 investment case for Oncolytics